Obstetrics & Gynaecology

Top Medical News
Supplementation with essential amino acid improves liver health in adolescents with PCOS
Rachel Tang, 2 days ago
Short-term supplementation with a selective essential amino acid (EAA)-containing product significantly improved liver-related outcomes among female adolescents with polycystic ovarian syndrome (PCOS) in a recent study.
Vitamin D insufficiency in early pregnancy highly prevalent in SG
Jairia Dela Cruz, 17 Apr 2024
A local study has raised concerns about a high rate of hypovitaminosis D in early pregnancy in Singapore.
Is a second pre-eclampsia more dangerous than the first event?
16 Apr 2024
A second pre-eclampsia does not lead to worse outcomes relative to the first occurrence, suggests a study. On the contrary, some clinical features and effects appear to be better in the second event.
Gestational Diabetes Mellitus
Kanas Chan, 16 Apr 2024

Gestational diabetes mellitus (GDM) is not associated with attention-deficit/hyperactivity disorder (ADHD) in offspring, a 20-year multinational study has shown.

Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients
Stephen Padilla, 12 Apr 2024
Patients with gynaecologic cancer who used apixaban for postoperative venous thromboembolism (VTE) prophylaxis achieve similar 90-day and lower 30-day rates of VTE when compared with those who used enoxaparin, reports a study presented at SGO 2024.
Maintenance fuzuloparib prolongs survival in ovarian cancer
Stephen Padilla, 12 Apr 2024
Maintenance therapy with fuzuloparib results in significant improvements in progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, who showed response to first-line platinum-based chemotherapy (PBC), reports a study (FZOCUS-1) presented at SGO 2024.
Does teen pregnancy foretell subsequent risk of premature death?
12 Apr 2024
Teenage pregnancy has been linked to an increased risk of premature mortality in early adulthood in a recent study.
Special Reports
Management of recurrent implantation failure during the COVID-19 pandemic
Dr. Ameet Patki, Dr. Prakash Mayandi, 22 Mar 2022
Recurrent implantation failure (RIF) refers to the failure to achieve a clinical pregnancy after three in vitro fertilization (IVF) attempts with at least four good-quality embryos. RIF leaves couples frustrated and desperate for answers and is challenging for clinicians to handle, compounded by the impact of the COVID-19 pandemic restrictions. Two experts, Dr Ameet Patki, Medical Director of Fertility Associates Mumbai and Hon Assoc Prof at KJ Somaiya Medical College & Hospital, India, and Dr Prakash Mayandi, Metro IVF Fertility Centre, Kuala Lumpur, Malaysia, weigh in with their views on managing RIF during the COVID-19 pandemic.
MONALEESA-2: Compelling survival data with ribociclib a ‘step forward’ in HR+/HER2- ABC
15 Nov 2021
Adding ribociclib (KISQALI, Novartis) to letrozole yields significant and consistent overall survival (OS) benefit compared with letrozole alone in the first-line setting for postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2-) advanced breast cancer (ABC), according to the final OS analysis of the MONALEESA-2 trial presented at ESMO 2021.
The changing treatment landscape for premenopausal women with advanced breast cancer: Focus on ribociclib
Dr. Wong Seng Weng, Dr. Lee Guek Eng, 19 Mar 2021
In Singapore, advanced breast cancer (aBC) is the leading cause of cancer death in women 30–49 years of age. For premenopausal women diagnosed with hormone receptor (HR)-positive, HER2-negative BC, cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors provide new hope. Currently, ribociclib is the only CDK4/6 inhibitor studied in the first-line setting for premenopausal women with HR+/HER2- aBC, in the phase III MONALEESA-7 trial. Two experts, Dr Wong Seng Weng, Medical Director & Consultant Medical Oncologist at The Cancer Centre, Paragon Medical & Mount Elizabeth Novena Specialist Centre, and Dr Lee Guek Eng, Senior Consultant & Specialist in Medical Oncology at Icon Cancer Centre and Program Director of the Young Women Cancer Program, weigh in with their views on managing premenopausal women with aBC.
Atezolizumab + chemo gets greenlight from HSA for PD-L1+ TNBC
Pearl Toh, 15 Aug 2020
Atezolizumab, in combination with the chemotherapy nab-paclitaxel, has been approved by the Singapore Health Sciences Authority (HSA) for the first-line treatment of unresectable locally advanced or metastatic, PD-L1-positive (PD-L1+) triple-negative breast cancer (TNBC) — adding to the growing market list this drug has been granted approval for TNBC.
Antioxidant and micronutrient supplementation on the sperm parameters of male patients with idiopathic infertility: An update
09 Jun 2020
Infertility is a problem faced by 5-10 percent of couples, with male factor accounting for up to 47 percent of cases. [Int J Androl 1987;7(Suppl):1]. There are many causes for male infertility but up to 15 percent of cases are idiopathic in nature. These cases may be related to unregulated excessive oxidative stress, which may impair spermatogenesis; hence, arousing research into the role of antioxidant supplementation in improving the sperm parameters.
Expert consensus: Patient profile should
guide antihistamine choice in primary care setting
10 Dec 2019
Oral H1-antihistamines are the initial treatment of choice for allergic rhinitis (AR) and chronic urticaria in the primary care setting. However, in a diverse population of patients with AR and urticaria, primary care physicians are faced with the challenge of prescribing the best therapy amid a wide armamentarium of antihistamines available.
The safe and rational use of ulipristal for fibroids
Dr. Siow Yew Ming Anthony, 20 Jun 2019
Fibroids or leiomyomas are the most common benign smooth muscle tumours of the uterus. They are often detected at screening ultrasound in asymptomatic patients. A fibroid will naturally grow until menopause and subsequently shrink when female hormone levels drop.
Conference Reports
Apixaban cheaper, on par with enoxaparin as VTE prophylaxis in gynaecologic cancer patients
Stephen Padilla, 12 Apr 2024
Patients with gynaecologic cancer who used apixaban for postoperative venous thromboembolism (VTE) prophylaxis achieve similar 90-day and lower 30-day rates of VTE when compared with those who used enoxaparin, reports a study presented at SGO 2024.
Maintenance fuzuloparib prolongs survival in ovarian cancer
Stephen Padilla, 12 Apr 2024
Maintenance therapy with fuzuloparib results in significant improvements in progression-free survival (PFS) in patients newly diagnosed with advanced ovarian cancer, who showed response to first-line platinum-based chemotherapy (PBC), reports a study (FZOCUS-1) presented at SGO 2024.
Niraparib maintenance yields favourable OS trend in patients with ovarian cancer
Elaine Soliven, 12 Apr 2024

Maintenance treatment with niraparib, a potent, highly selective PARP* inhibitor, provides a favourable overall survival (OS) trend compared with placebo in Chinese patients with platinum-sensitive recurrent ovarian cancer (PSROC), regardless of germline BRCA (gBRCA) mutation status, according to the final analysis of the NORA trial presented at SGO 2024.

Survival outcomes similar between minimally invasive interval debulking surgery and laparotomy
Jairia Dela Cruz, 05 Apr 2024
A minimally invasive approach to interval debulking surgery appears to be just as effective as the use of an open technique for epithelial ovarian cancer, with no significant difference in overall survival (OS) when complete tumour resection is achieved, according to a study.
Noninvasive device targets precancerous cervical lesions with minimal risk
Jairia Dela Cruz, 04 Apr 2024
A novel device that integrates hexaminolevulinate (HAL) hydrochloride (HCl) with photodynamic therapy for the treatment of cervical histologic high-grade squamous intraepithelial lesions (HSIL) has shown good results in the global phase III APRICITY study, with lasting efficacy and an acceptable safety profile.
Pembrolizumab plus chemo ups survival in advanced endometrial cancer across MMR subgroups
Elaine Soliven, 02 Apr 2024

Adding pembrolizumab to standard chemotherapy resulted in a favourable overall survival (OS) benefit in patients with advanced or recurrent endometrial cancer compared with chemotherapy alone, regardless of mismatch repair (MMR) status, according to a key prespecified secondary analysis of the NRG-GY018 trial presented at the SGO 2024.

Breastfeeding delivers long-term cardiometabolic benefits in offspring
Audrey Abella, 27 Feb 2024
In a secondary analysis of the HAPO FUS*, breastfeeding was found to be associated with lower rate of glucose metabolism disorders in the offspring; however, this association was not seen among the mothers.